Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection
Background & Aims
We compared 5 non-specific and 2 specific blood tests for liver fibrosis in HCV/HIV co-infection.
Methods
Four hundred and sixty-seven patients were included into derivation (n
=
183) or validation (n
=
284) populations. Within these populations, the diagnostic target, significant fibrosis (Metavir F ⩾2), was found in 66% and 72% of the patients, respectively. Two new fibrosis tests, FibroMeter HICV and HICV test, were constructed in the derivation population.
Results
Unadjusted AUROCs in the derivation population were: APRI: 0.716, Fib-4: 0.722, Fibrotest: 0.778, Hepascore: 0.779, FibroMeter: 0.783, HICV test: 0.822, FibroMeter HICV: 0.828. AUROCs adjusted on classification and distribution of fibrosis stages in a reference population showed similar values in both populations. FibroMeter, FibroMeter HICV and HICV test had the highest correct classification rates in F0/1 and F3/4 (which account for high predictive values): 77–79% vs. 70–72% in the other tests (p
=
0.002). Reliable individual diagnosis based on predictive values ⩾90% distinguished three test categories: poorly reliable: Fib-4 (2.4% of patients), APRI (8.9%); moderately reliable: Fibrotest (25.4%), FibroMeter (26.6%), Hepascore (30.2%); acceptably reliable: HICV test (40.2%), FibroMeter HICV (45.6%) (p
<
10−3 between tests). FibroMeter HICV classified all patients into four reliable diagnosis intervals (⩽F1, F1
±
1, ⩾F1, ⩾F2) with an overall accuracy of 93% vs. 79% (p
<
10−3) for a binary diagnosis of significant fibrosis.
Conclusions
Tests designed for HCV infections are less effective in HIV/HCV infections. A specific test, like FibroMeter HICV, was the most interesting test for diagnostic accuracy, correct classification profile, and a reliable diagnosis. With reliable diagnosis intervals, liver biopsy can therefore be avoided in all patients.
Abbreviations: APRI, aspartate aminotransferase to platelet ratio index, AST, aspartate aminotransferase, AUROC, area under the receiver operating characteristic, CLD, chronic liver disease, HCV, hepatitis C virus, HICV, human immunodeficiency and C virus (used for HICV fibrosis test), HIV, human immunodeficiency virus, NPV, negative predictive value, PPV, positive predictive value
Keywords: Liver fibrosis, Blood test, Hepatitis C virus, Human immunodeficiency virus, Metavir staging, Diagnostic test
To access this article, please choose from the options below
PII: S0168-8278(10)00271-0
doi:10.1016/j.jhep.2010.03.007
© 2010 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Serum fibrosis markers: Death by validation or a leap of faith? , 11 May 2010
